|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ikeda K, Saitoh S, Koida I, Arase Y,
Tsubota A, Chayama K, Kumada H and Kawanishi M: A multivariate
analysis of risk factors for hepatocellular carcinogenesis: A
prospective observation of 795 patients with viral and alcoholic
cirrhosis. Hepatology. 18:47–53. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang W, Zhao G, Wei K, Zhang Q, Ma W,
Song T, Wu Q, Zhang T, Kong D and Li Q: Adjuvant sorafenib reduced
mortality and prolonged overall survival and post-recurrence
survival in hepatocellular carcinoma patients after curative
resection: A single-center experience. Biosci Trends. 8:333–338.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang SN, Chuang SC and Lee KT: Efficacy of
sorafenib as adjuvant therapy to prevent early recurrence of
hepatocellular carcinoma after curative surgery: A pilot study.
Hepatol Res. 44:523–531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung YH, Han G, Yoon JH, Yang J, Wang J,
Shao GL, Kim BI, Lee TY and Chao Y: Interim analysis of START:
Study in Asia of the combination of TACE (transcatheter arterial
chemoembolization) with sorafenib in patients with hepatocellular
carcinoma trial. Int J Cancer. 132:2448–2458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Culp SH, Tannir NM, Abel EJ, Margulis V,
Tamboli P, Matin SF and Wood CG: Can we better select patients with
metastatic renal cell carcinoma for cytoreductive nephrectomy?
Cancer. 116:3378–3388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Albiges L, Kube U, Eymard JC, Schmidinger
M, Bamias A, Kelkouli N, Mraz B, Florini S, Guderian G, Cattaneo A,
et al: Everolimus for patients with metastatic renal cell carcinoma
refractory to anti-VEGF therapy: Results of a pooled analysis of
non-interventional studies. Eur J Cancer. 51:2368–2374. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oudard S and Vano Y: The role of
rechallenge with targeted therapies in metastatic renal-cell
carcinoma. Curr Opin Urol. 25:402–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eichelberg C, Vervenne WL, De Santis M,
von Weikersthal Fischer L, Goebell PJ, Lerchenmüller C, Zimmermann
U, Bos MM, Freier W, Schirrmacher-Memmel S, et al: SWITCH: A
Randomised, Sequential, Open-label Study to Evaluate the Efficacy
and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the
Treatment of Metastatic Renal Cell Cancer. Eur Urol. 68:837–847.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barone C, Basso M, Biolato M, Pompili M,
Rufini V, Miele L, Basso M, De Gaetano AM, Castaldi P, Iaculli A,
et al: A phase II study of sunitinib in advanced hepatocellular
carcinoma. Dig Liver Dis. 45:692–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng AL, Kang YK, Lin DY, Park JW, Kudo
M, Qin S, Chung HC, Song X, Xu J, Poggi G, et al: Sunitinib versus
sorafenib in advanced hepatocellular cancer: Results of a
randomized phase III trial. J Clin Oncol. 31:4067–4075. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Majumder S, Piguet AC, Dufour JF and
Chatterjee S: Study of the cellular mechanism of sunitinib mediated
inactivation of activated hepatic stellate cells and its
implications in angiogenesis. Eur J Pharmacol. 705:86–95. 2013.
View Article : Google Scholar : PubMed/NCBI
|
